Field performance and acceptability of the hepatitis B core-related antigen rapid diagnostic test (HBcrAg-RDT) for detecting high viral load among pregnant women in The Gambia (PROTECT-B)

Clicks: 2
ID: 313812
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #415 of 531 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 531 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Mother-to-child transmission remains a major source of chronic hepatitis B virus (HBV) infection globally. Identifying pregnant women eligible for antiviral prophylaxis requires HBV DNA testing, which is often inaccessible in resource-limited settings. The hepatitis B core-related antigen rapid diagnostic test (HBcrAg-RDT) may offer a point-of-care alternative, yet prospective evaluation in antenatal care is lacking. We assessed its diagnostic performance, clinical impact, and user acceptability within an HIV/syphilis/HBV triple elimination program. METHODS: In this multicenter prospective cross-sectional study, treatment-naïve, HBsAg-positive pregnant women were enrolled across four antenatal services in The Gambia. Diagnostic accuracy of the HBcrAg-RDT for detecting high viral load (≥200,000 IU/mL) was evaluated using plasma and capillary whole blood samples, with GeneXpert HBV viral load as the reference standard. RESULTS: 5.5% of 343 HBsAg-positive pregnant women had high viral load. The HBcrAg-RDT demonstrated 89.5% (95%CI 66.9-98.7) sensitivity and 98.5% (95%CI 96.4-99.5) specificity with plasma, and 88.2% (95%CI 63.6-98.5) sensitivity and 98.7% (95%CI 96.6-99.6) specificity with capillary blood. At one site implementing universal tenofovir prophylaxis, 77 women started treatment, of whom only four had HBV DNA ≥200,000 IU/mL. An HBcrAg-RDT-guided strategy would have identified all eligible women (4/4) while reducing unnecessary treatment from 100% (73/73) to 4.1% (3/73). Users rated the test highly for ease of use, although incubation time modestly increased workload. CONCLUSION: The HBcrAg-RDT accurately identified pregnant women requiring antiviral prophylaxis and was accepted by users. It represents a feasible, lower-cost alternative to HBV DNA testing and may reduce unnecessary tenofovir use compared with universal prophylaxis strategies.
Reference Key
openalex_W7160951401 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Alexandra M Famiglietti, Sainabou Drammeh, E. Vo Quang, Bakary Dibba, Kitabu Jammeh, Abdoulie E Jallow, Alhagie Touray, Saikou Keita, Yassin Gaye, Baboucarr Manneh, Yahya Sallah, Sheriff Badjie, Sylvie Boyer, Lauren Périères, Laurène Petitfour, S A Khan, Alice N Guingané, Abdoul Tiendrebeogo, Dramane Kania, Umberto D’Alessandro, Yasuhito Tanaka, Maud Lemoine, Gibril Ndow, Yusuke Shimakawa
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag311
URL
https://doi.org/10.1093/cid/ciag311
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.